OBJECTIVES/HYPOTHESIS: To determine whether the result of first posttreatment positron emission tomography and computed tomography (PET/CT) is predictive of outcome in patients with oropharyngeal squamous cell carcinoma (OPSCC), and whether PET/CT accuracy is affected by human papillomavirus (HPV) status. STUDY DESIGN: Retrospective review. METHODS: Demographic, clinical, and radiographic data were available for 61 patients with OPSCC, treated in 2004 to 2012 at a single tertiary academic referral center, with at least one baseline and one posttreatment PET/CT. Clinical follow-up was obtained every 3 months thereafter. The median follow-up time was 36 months (range 3-100 months). RESULTS: Of 61 patients, 48 (79%) had negative first posttreatment PET/CT results; and overall, 18 of the 61 patients (30%) recurred. All accuracy measures for PET/CT were higher in HPV-positive patients, including a 93% negative predictive value (NPV). Patients with positive PET/CT results had poorer survival on Kaplan-Meier analyses. On multivariate analysis of factors predictive of recurrence, two parameters were significant: HPV status (P = 0.0046) and PET/CT result (P <0.0001). CONCLUSIONS: A negative first posttreatment PET/CT result is associated with better prognosis and rare recurrence, especially in patients with HPV-positive status. Less frequent radiologic surveillance is warranted in patients with HPV-positive OPSCC and a negative first posttreatment PET/CT scan.
OBJECTIVES/HYPOTHESIS: To determine whether the result of first posttreatment positron emission tomography and computed tomography (PET/CT) is predictive of outcome in patients with oropharyngeal squamous cell carcinoma (OPSCC), and whether PET/CT accuracy is affected by human papillomavirus (HPV) status. STUDY DESIGN: Retrospective review. METHODS: Demographic, clinical, and radiographic data were available for 61 patients with OPSCC, treated in 2004 to 2012 at a single tertiary academic referral center, with at least one baseline and one posttreatment PET/CT. Clinical follow-up was obtained every 3 months thereafter. The median follow-up time was 36 months (range 3-100 months). RESULTS: Of 61 patients, 48 (79%) had negative first posttreatment PET/CT results; and overall, 18 of the 61 patients (30%) recurred. All accuracy measures for PET/CT were higher in HPV-positive patients, including a 93% negative predictive value (NPV). Patients with positive PET/CT results had poorer survival on Kaplan-Meier analyses. On multivariate analysis of factors predictive of recurrence, two parameters were significant: HPV status (P = 0.0046) and PET/CT result (P <0.0001). CONCLUSIONS: A negative first posttreatment PET/CT result is associated with better prognosis and rare recurrence, especially in patients with HPV-positive status. Less frequent radiologic surveillance is warranted in patients with HPV-positive OPSCC and a negative first posttreatment PET/CT scan.
Authors: A Gore; K Baugnon; J Beitler; N F Saba; M R Patel; X Wu; B J Boyce; A H Aiken Journal: AJNR Am J Neuroradiol Date: 2020-06-18 Impact factor: 3.825
Authors: Sweet Ping Ng; Courtney Pollard; Joel Berends; Zeina Ayoub; Mona Kamal; Adam S Garden; Houda Bahig; Scott B Cantor; Andrew J Schaefer; Temitayo Ajayi; G Brandon Gunn; Steven J Frank; Heath Skinner; Jack Phan; William H Morrison; Renata Ferrarotto; Jason M Johnson; Abdallah S R Mohamed; Stephen Y Lai; Amy C Hessel; Erich M Sturgis; Randal S Weber; Clifton D Fuller; David I Rosenthal Journal: Cancer Date: 2019-02-12 Impact factor: 6.860
Authors: Mehdi Taghipour; Esther Mena; Matthew J Kruse; Sara Sheikhbahaei; Rathan M Subramaniam Journal: Nucl Med Commun Date: 2017-03 Impact factor: 1.690
Authors: D A Krieger; P A Hudgins; G K Nayak; K L Baugnon; A S Corey; M R Patel; J J Beitler; N F Saba; Y Liu; A H Aiken Journal: AJNR Am J Neuroradiol Date: 2017-03-31 Impact factor: 3.825
Authors: S Connor; C Sit; M Anjari; M Lei; T Guerrero-Urbano; T Szyszko; G Cook; P Bassett; V Goh Journal: J Cancer Res Clin Oncol Date: 2021-06-22 Impact factor: 4.553